feed,title,long_url,short_url
Benzinga,Novo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review,https://benzinga.com/general/biotech/24/05/38969986/novo-nordisks-once-weekly-insulin-flagged-with-risk-of-low-blood-sugar-ahead-of-fda-review,https://da.gd/wzzi1
Benzinga,Stryker Stock Is Attractive Considering Its Double-Digit Organic Revenue Growth - Analyst Upgrades Stock,https://benzinga.com/news/24/05/38969957/stryker-stock-is-attractive-considering-its-double-digit-organic-revenue-growth-analyst-upgrades-sto,https://da.gd/eJM25
